Posted by Michael Wonder on 09 Aug 2024
Enzalutamide for the treatment of patients with non-metastatic prostate cancer after radical prostatectomy or radiotherapy
8 August 2024 - NICE is unable to make a recommendation about the use in the NHS of enzalutamide for the treatment of patients with non-metastatic prostate cancer after radical prostatectomy or radiotherapy because Astellas Pharma did not provide an evidence submission.
NICE will review this decision if Astellas decides to make a submission.
